Trastuzumab Deruxtecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer Metastatic
Conditions
Breast Cancer Metastatic
Trial Timeline
Jun 20, 2025 → Dec 31, 2028
NCT ID
NCT06750484About Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Breast Cancer Metastatic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06750484. Target conditions include Breast Cancer Metastatic.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer Metastatic were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in Breast Cancer Metastatic